NCT04346017View on ClinicalTrials.gov

Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome

NACompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 20, 2020

Primary Completion Date

November 23, 2020

Study Completion Date

November 23, 2020

Conditions
COVID-19
Interventions
DIAGNOSTIC_TEST

Cytokines dosage

Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).

DIAGNOSTIC_TEST

Complement dosage

Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.

Trial Locations (1)

1020

CHU Brugmann, Brussels

All Listed Sponsors
lead

Francis Corazza

OTHER

NCT04346017 - Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome | Biotech Hunter | Biotech Hunter